| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
|
Nature
|
2006
|
27.91
|
|
2
|
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
|
Proc Natl Acad Sci U S A
|
2013
|
6.88
|
|
3
|
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
|
Cancer Res
|
2006
|
6.77
|
|
4
|
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
|
J Clin Oncol
|
2010
|
6.30
|
|
5
|
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
|
Cancer Cell
|
2009
|
5.81
|
|
6
|
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
|
Cancer Res
|
2004
|
4.26
|
|
7
|
Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
|
Nature
|
2012
|
4.13
|
|
8
|
Phase II trial of gefitinib in recurrent glioblastoma.
|
J Clin Oncol
|
2003
|
3.83
|
|
9
|
Integrin alpha 6 regulates glioblastoma stem cells.
|
Cell Stem Cell
|
2010
|
3.82
|
|
10
|
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.
|
Cell Cycle
|
2009
|
3.55
|
|
11
|
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.
|
Cell
|
2013
|
3.32
|
|
12
|
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.
|
Cancer Cell
|
2009
|
3.11
|
|
13
|
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
|
Neuro Oncol
|
2007
|
2.99
|
|
14
|
Targeting cancer stem cells through L1CAM suppresses glioma growth.
|
Cancer Res
|
2008
|
2.97
|
|
15
|
The integrated landscape of driver genomic alterations in glioblastoma.
|
Nat Genet
|
2013
|
2.89
|
|
16
|
Gene expression profiling and genetic markers in glioblastoma survival.
|
Cancer Res
|
2005
|
2.63
|
|
17
|
c-Myc is required for maintenance of glioma cancer stem cells.
|
PLoS One
|
2008
|
2.41
|
|
18
|
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.
|
Cancer Res
|
2005
|
2.35
|
|
19
|
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
|
J Clin Oncol
|
2008
|
2.32
|
|
20
|
Phase II trial of temozolomide in patients with progressive low-grade glioma.
|
J Clin Oncol
|
2003
|
2.16
|
|
21
|
An animal model of MYC-driven medulloblastoma.
|
Cancer Cell
|
2012
|
2.12
|
|
22
|
Brain cancer stem cells display preferential sensitivity to Akt inhibition.
|
Stem Cells
|
2008
|
2.12
|
|
23
|
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
|
Cancer Cell
|
2011
|
2.04
|
|
24
|
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
|
Neuro Oncol
|
2010
|
1.99
|
|
25
|
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.
|
Stem Cells
|
2009
|
1.97
|
|
26
|
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.
|
Oncotarget
|
2010
|
1.88
|
|
27
|
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2005
|
1.85
|
|
28
|
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.
|
Clin Cancer Res
|
2003
|
1.85
|
|
29
|
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.
|
Cancer Res
|
2009
|
1.77
|
|
30
|
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.
|
Cell
|
2011
|
1.77
|
|
31
|
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
|
Mol Cancer Ther
|
2005
|
1.66
|
|
32
|
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
|
J Neurooncol
|
2009
|
1.65
|
|
33
|
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
|
J Clin Oncol
|
2005
|
1.63
|
|
34
|
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
|
J Neurooncol
|
2003
|
1.63
|
|
35
|
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
|
Clin Cancer Res
|
2006
|
1.63
|
|
36
|
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition.
|
Arch Pathol Lab Med
|
2008
|
1.61
|
|
37
|
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
|
Neuro Oncol
|
2008
|
1.59
|
|
38
|
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
|
Neuro Oncol
|
2010
|
1.59
|
|
39
|
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
|
J Nucl Med
|
2007
|
1.57
|
|
40
|
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
|
Blood
|
2011
|
1.54
|
|
41
|
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
|
J Clin Oncol
|
2009
|
1.53
|
|
42
|
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
|
J Clin Oncol
|
2002
|
1.50
|
|
43
|
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
|
Cancer Res
|
2012
|
1.46
|
|
44
|
Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats.
|
J Toxicol Environ Health A
|
2008
|
1.41
|
|
45
|
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
|
Oncotarget
|
2014
|
1.40
|
|
46
|
EGFRvIII-targeted vaccination therapy of malignant glioma.
|
Brain Pathol
|
2009
|
1.40
|
|
47
|
MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
|
Arch Pathol Lab Med
|
2002
|
1.37
|
|
48
|
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
|
Acta Neuropathol
|
2013
|
1.35
|
|
49
|
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
|
J Clin Oncol
|
2002
|
1.32
|
|
50
|
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells.
|
PLoS One
|
2011
|
1.29
|
|
51
|
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
|
J Neurooncol
|
2011
|
1.29
|
|
52
|
Targeting A20 decreases glioma stem cell survival and tumor growth.
|
PLoS Biol
|
2010
|
1.27
|
|
53
|
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
|
Clin Cancer Res
|
2002
|
1.27
|
|
54
|
Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.25
|
|
55
|
Protocol for the examination of specimens from patients with tumors of the brain/spinal cord.
|
Arch Pathol Lab Med
|
2008
|
1.25
|
|
56
|
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
|
Neurosurgery
|
2002
|
1.23
|
|
57
|
A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
|
Biochem Biophys Res Commun
|
2009
|
1.22
|
|
58
|
Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007.
|
Cancer
|
2012
|
1.20
|
|
59
|
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
|
J Natl Compr Canc Netw
|
2011
|
1.16
|
|
60
|
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
|
Clin Cancer Res
|
2005
|
1.16
|
|
61
|
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
|
Cancer
|
2011
|
1.16
|
|
62
|
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways.
|
Proc Natl Acad Sci U S A
|
2012
|
1.14
|
|
63
|
Laminin alpha 2 enables glioblastoma stem cell growth.
|
Ann Neurol
|
2012
|
1.13
|
|
64
|
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
|
Mol Cancer Ther
|
2006
|
1.13
|
|
65
|
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
|
J Clin Oncol
|
2006
|
1.12
|
|
66
|
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
|
J Clin Oncol
|
2003
|
1.11
|
|
67
|
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
|
Clin Cancer Res
|
2008
|
1.10
|
|
68
|
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
|
J Neurooncol
|
2007
|
1.10
|
|
69
|
The genetic landscape of anaplastic astrocytoma.
|
Oncotarget
|
2014
|
1.09
|
|
70
|
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
|
Biochem Biophys Res Commun
|
2010
|
1.08
|
|
71
|
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
|
J Nucl Med
|
2005
|
1.08
|
|
72
|
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
|
PLoS One
|
2012
|
1.08
|
|
73
|
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
|
Clin Cancer Res
|
2013
|
1.07
|
|
74
|
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.
|
Clin Cancer Res
|
2013
|
1.06
|
|
75
|
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
|
J Neurooncol
|
2010
|
1.06
|
|
76
|
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
|
Oncotarget
|
2013
|
1.06
|
|
77
|
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells.
|
Stem Cells
|
2014
|
1.05
|
|
78
|
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
|
Am J Surg Pathol
|
2003
|
1.04
|
|
79
|
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.
|
Genes Cancer
|
2010
|
1.03
|
|
80
|
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
|
Acta Neuropathol
|
2007
|
1.02
|
|
81
|
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.
|
J Clin Invest
|
2014
|
1.02
|
|
82
|
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
|
Neuro Oncol
|
2002
|
1.00
|
|
83
|
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
|
Clin Cancer Res
|
2013
|
1.00
|
|
84
|
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
|
J Neurooncol
|
2012
|
1.00
|
|
85
|
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
|
Nucl Med Biol
|
2011
|
0.99
|
|
86
|
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
|
Neuro Oncol
|
2008
|
0.99
|
|
87
|
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
|
J Neurooncol
|
2011
|
0.98
|
|
88
|
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
|
Neuro Oncol
|
2005
|
0.98
|
|
89
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
|
90
|
The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis.
|
Virology
|
2003
|
0.97
|
|
91
|
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
|
J Clin Invest
|
2014
|
0.97
|
|
92
|
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
|
Neuro Oncol
|
2008
|
0.96
|
|
93
|
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
|
BMC Cancer
|
2010
|
0.96
|
|
94
|
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
|
J Neurooncol
|
2011
|
0.96
|
|
95
|
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
|
Cancer Res
|
2006
|
0.95
|
|
96
|
A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.
|
PLoS One
|
2013
|
0.95
|
|
97
|
Molecular markers of prognosis in astrocytic tumors.
|
Cancer
|
2002
|
0.93
|
|
98
|
A comprehensive analysis of 41 patients with rosette-forming glioneuronal tumors of the fourth ventricle.
|
J Clin Neurosci
|
2013
|
0.92
|
|
99
|
Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors.
|
J Neurooncol
|
2014
|
0.92
|
|
100
|
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.91
|
|
101
|
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
|
Nucl Med Biol
|
2009
|
0.91
|
|
102
|
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
|
J Neurooncol
|
2012
|
0.89
|
|
103
|
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
|
Clin Cancer Res
|
2007
|
0.89
|
|
104
|
GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.
|
Biochem Biophys Res Commun
|
2009
|
0.87
|
|
105
|
Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.
|
Cancer Res
|
2009
|
0.87
|
|
106
|
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
|
Clin Cancer Res
|
2009
|
0.87
|
|
107
|
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
|
Neuro Oncol
|
2009
|
0.87
|
|
108
|
Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.
|
Neuro Oncol
|
2002
|
0.87
|
|
109
|
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
|
Int J Cancer
|
2010
|
0.87
|
|
110
|
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
|
J Neurooncol
|
2009
|
0.86
|
|
111
|
Intraaxial dermoid cyst of the medulla.
|
J Neurosurg
|
2013
|
0.85
|
|
112
|
Chordoid glioma: a case report and molecular characterization of five cases.
|
Brain Pathol
|
2008
|
0.84
|
|
113
|
Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.
|
J Mol Diagn
|
2004
|
0.83
|
|
114
|
IDH1 and IDH2 hotspot mutations are not found in canine glioma.
|
Int J Cancer
|
2010
|
0.83
|
|
115
|
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
|
J Neurooncol
|
2006
|
0.83
|
|
116
|
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
|
J Neurooncol
|
2012
|
0.83
|
|
117
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
|
118
|
Central nervous system.
|
Cancer Biomark
|
2010
|
0.82
|
|
119
|
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
|
J Nucl Med
|
2006
|
0.82
|
|
120
|
Few isolated neurons in hypothalamic hamartomas may cause gelastic seizures.
|
Pediatr Neurosurg
|
2009
|
0.81
|
|
121
|
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
|
Cancer
|
2009
|
0.81
|
|
122
|
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.
|
Arch Pathol Lab Med
|
2015
|
0.81
|
|
123
|
Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
|
J Neurosurg
|
2008
|
0.81
|
|
124
|
Clinicopathological characteristics and treatment of rhabdoid glioblastoma.
|
J Neurosurg
|
2013
|
0.81
|
|
125
|
Single-stage bilateral choroid plexectomy for choroid plexus papilloma in a patient presenting with high cerebrospinal fluid output.
|
J Neurosurg Pediatr
|
2010
|
0.80
|
|
126
|
Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis.
|
BMC Dev Biol
|
2010
|
0.80
|
|
127
|
Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
|
Clin Cancer Res
|
2002
|
0.79
|
|
128
|
Choroid plexus papilloma with neuropil-like islands.
|
Am J Surg Pathol
|
2008
|
0.79
|
|
129
|
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
|
Neurol Med Chir (Tokyo)
|
2006
|
0.77
|
|
130
|
Accreditation council for graduate medical education (ACGME) competencies in neuropathology training.
|
J Neuropathol Exp Neurol
|
2005
|
0.77
|
|
131
|
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
|
J Neurooncol
|
2013
|
0.77
|
|
132
|
Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
|
Hybridoma (Larchmt)
|
2009
|
0.76
|
|
133
|
Cerebellopontine angle craniopharyngioma: case report and literature review.
|
Pediatr Neurosurg
|
2007
|
0.75
|
|
134
|
Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.
|
Mod Pathol
|
2004
|
0.75
|
|
135
|
Clinical data simplified.
|
J Neurosurg
|
2011
|
0.75
|
|
136
|
Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
|
Arch Pathol Lab Med
|
2017
|
0.75
|
|
137
|
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
|
J Neurooncol
|
2009
|
0.75
|
|
138
|
Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease.
|
J Clin Neurosci
|
2013
|
0.75
|
|
139
|
Progressive multifocal leukoencephalopathy with occult Waldenström macroglobulinemia.
|
J Clin Oncol
|
2010
|
0.75
|
|
140
|
A recurrent cerebellar lesion in a young boy.
|
Brain Pathol
|
2008
|
0.75
|
|
141
|
Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR.
|
Acta Neuropathol
|
2006
|
0.75
|